Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Rocephin injection for otitis media approved Dec. 23 as first single-dose regimen for indication.

Executive Summary

ROCHE ROCEPHIN IS FIRST SINGLE-DOSE OTITIS MEDIA ANTIBIOTIC following approval of Roche's supplemental NDA 50-585/S-046 by FDA on Dec. 23. The new indication for Rocephin (ceftriaxone) intramuscular injection covers acute otitis media due to Streptococcus pneumoniae and beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis. The 13 other antibiotics approved for otitis media are all orally administered and require a five- to 10-day dosing regimen, which can complicate compliance.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS031464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel